
Employers Are Dropping Coverage For GLP-1 Weight Loss Drugs: What It Means For Patients
What Happened?
Several US employers are discontinuing insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, raising concerns about affordability and access for patients. The decline in coverage is attributed to rising treatment costs.
Key points
- Insurance coverage for GLP-1 medications for weight loss dropped from 57% to 53% in 2026.
- 91% of employers dropping coverage cited cost as the main reason.
- PepsiCo has stopped covering weight-loss medications while still covering GLP-1 drugs for diabetes.
- Cigna discontinued weight-loss GLP-1 coverage under its employee health plan from July 2026.
- 67% of surveyed employers still cover GLP-1 medications for weight management.
Key insights
- Patients may face higher out-of-pocket costs or switch treatments due to loss of coverage.
- Continuity of care is crucial as discontinuing treatment could lead to weight regain.
- Employers are balancing healthcare needs with financial sustainability, affecting employee health.
Why it matters
The changes in coverage could significantly impact patients' access to essential weight-loss medications.
Tags
Entities
Source
Times Now
